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Objectives: This literature review aims to summarize the effects of medical cannabis use in 
children on Autism Spectrum Disorder (ASD) symptoms, side effects and provide 
recommendations for practice, education, and research. Background: ASD is characterized by 
core behaviors of significant impairment in social communication and interaction and restricted 
and repetitive patterns of behavior, interests, or activities (APA, 2013). In addition to these core 
behaviors, individuals with ASD often have noncore behavioral disorders and several medical 
comorbidities. Treatment for ASD symptoms includes Cognitive Behavioral Therapy (CBT), 
aripiprazole (Abilify) and/or risperidone (Risperdal). As of this review, 14 states have added 
ASD as a qualifying condition in their medical cannabis program. Methods: Key terms related to 
the clinical question were entered into eight different databases to search for studies on cannabis 
use in children with ASD. Findings: The findings suggest improvement in ASD symptoms, such 
as social communication (core symptom), noncore behaviors (self-injury, restlessness, rage 
attacks, agitation, aggressiveness, irritability), and comorbid conditions (anxiety, epilepsy, sleep 
problems/dysregulation, ADHD/hyperactivity/concentration). An additional benefit with the 
improvement in comorbid conditions is the reduction of medications used in some participants. 
Common side effects include sleep disturbance, somnolence, and decreased appetite, 
restlessness, and a single episode of psychosis requiring treatment. These studies' positive 
outcomes warrant the use of cannabis as an adjunct treatment in children and provide the impetus 
for further research studies with large randomized controlled trials to provide higher evidence 
literature to support the treatment of ASD symptoms with cannabis.  
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Limited Studies on Cannabis Treatment of Autism in Children: A Literature Review 
 Cannabis was first legalized for medical use in 1996 when California passed Proposition 
215 (National Conference of State Legislatures [NCSL], 2021). Since then, 35 states, the District 
of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands, have enacted similar laws (NCSL, 
2021). Medical cannabis use is limited to qualifying conditions established by each 
state/territory, resulting in differing qualifying conditions (Boehnke et al., 2019). As of this 
review, autism is a qualifying condition for medical cannabis in 14 states (Colorado, Delaware, 
Georgia, Illinois, Iowa, Louisiana, Michigan, Minnesota, Missouri, New Mexico, Pennsylvania, 
Rhode Island, Texas, Utah) and the Territory of Puerto Rico (Mothers Advocating Medical 
Marijuana for Autism [MAMMA], n.d.). 
 The literature has established the human endocannabinoid system (ECS) as a significant 
regulator of multiple functions in the brain and throughout the body (Blessing et al., 2015; 
Chakrabarti et al., 2015; Meyer et al., 2018; Zou & Kumar, 2018). The ECS regulates emotional 
behaviors (Blessing et al., 2015), stress, fear, anxiety (Blessing et al., 2015; Meyer et al., 2018), 
behavior reactivity to context, social interaction (Chakrabarti et al., 2015), learning, memory, 
cognition, appetite, reward and addiction, sleep, immunity modulation, pain (Brigida et al., 2017; 
Chakrabarti et al., 2015; Zou & Kumar, 2018) and many other functions. Rodent models have 
demonstrated that alterations in the ECS produced ASD-like symptoms (Zamberlettie et al., 
2017; Wei et al., 2016) such as “attention and working memory deficits, hyperactivity, repetitive 
behaviors, anxiety-related phenotypes, altered social behaviors, and increases susceptibility to 
audiogenic seizures” (Zamberlettie et al., 2017, p. 3). Modulation of the ECS in these rodent 
models improved behavioral deficits, anxiety (Blessings et al., 2015) and promoted social 
behaviors (Brigida et al., 2017; Zamberlettie et al., 2017; Wei et al., 2016). The results from 
                       
 
5 
these rodent studies and the established literature on the ECS make the use of exogenous 
phytocannabinoids, such as cannabidiol (CBD) and Delta (9)-tetrahydrocannabinol (THC), 
appealing treatment options for Autism Spectrum Disorder (ASD) symptoms.  
The safety of early-onset and long-term use of exogenous cannabinoids on the developing 
adolescent brain is unclear. This is primarily due to conflicting evidence (Burnett, 2016; Jacobus 
& Tapert, 2014; Lubman et al., 2015). Some studies suggest that adolescents frequently exposed 
to cannabis are at risk for cognitive impairment and increased risk of psychosis (Burnett, 2016; 
Lubman et al., 2015). Other studies report that cognitive impairment fully recovers after 
prolonged abstinence (Fried et al., 2005; Lubman et al., 2015). Teichner et al. (2000) reported no 
relationship between marijuana use severity and cognitive performance among cognitively 
impaired and unimpaired adolescents. The cognitive effects of cannabis on the developing brain 
are uncertain, due to the inconsistent reports. The ECS is a critical regulator in normal brain 
remodeling during adolescence (Lubman et al., 2015). Evidence indicates structural changes 
from prolonged cannabis exposure in the adolescent brain, such as alteration in synaptic pruning 
and white matter development (Battistella et al., 2014; Lubman et al., 2015). Changes in white 
matter tract integrity and abnormalities of neural functioning were also reported (Jacobus & 
Tapert, 2014), and reduced gray matter in regions of the brain functionally associated with 
motivational, emotional, and affective processing (Battistella et al., 2014). These studies suggest 
prolonged exposure during adolescence may be harmful to normal brain remodeling.  
Despite the uncertainty in the safety of cannabis use in adolescents and the developing 
brain, the preclinical data and literature on the ECS suggest a therapeutic potential in treating 
ASD symptoms with exogenous cannabinoids. This literature review aims to summarize the 
effects of cannabis on ASD symptoms (core behaviors, noncore behaviors) in children, 
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associated ASD comorbid conditions, cannabis side effects, and recommendations for practice, 
education, and research based on the evidence presented in studies selected for this systematic 
review. 
Background 
ASD is characterized by core symptoms of social and communication deficits and 
repetitive and restrictive sensory-motor behaviors (American Psychiatric Association, 2013). In 
addition to these core behaviors, behavioral problems (irritability, aggression, self-injury) and 
comorbid conditions (intellectual disability, anxiety, depression, attention-deficit/hyperactivity 
disorder [ADHD], sleep disorders, epilepsy, gastrointestinal dysfunction, immune deficiency) are 
often associated with ASD at higher incidence rates (Lukmanji et al., 2019; Neumeyer et al., 
2019; Rosen et al., 2018; Soke et al., 2016; Thomas et al., 207; Tye et al., 2018). 
The clinical phenomenon of interest  
 There is no treatment for ASD, but core symptoms and behavioral problems are often 
managed with Cognitive Behavioral Therapy (CBT) for cognitive, language, and adaptive skills 
training (National Center on Birth Defects and Developmental Disabilities [NCBDDD] & 
Centers for Disease Control and Prevention [CDC] 2019; Sanchack & Thomas, 2016). 
Pharmacotherapy is frequently used to treat behaviors not managed with CBT and comorbid 
conditions associated with ASD (Jobski et al., 2017; Sanchack & Thomas, 2016). The only 
atypical antipsychotics approved by the U.S. Food and Drug Administration (FDA) for treating 
ASD-associated irritability, aggression, explosive outburst, and self-injury are aripiprazole 
(Abilify) and risperidone (Risperdal) (Barnard-Brak et al., 2016; LeClerc & Easley, 2015; 
Sanchack & Thomas, 2016). Pharmacotherapies such as antipsychotics, mood stabilizers, 
antiepileptics, stimulants, and SSRIs are used “off label” in treating behaviors and core social 
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impairments in ASD despite their increased risk for adverse effects in children and little to no 
evidence to support their efficacy (Barnard-Brak et al., 2007; Jobski et al., 2017; LeClerc & 
Easley, 2015; McClellan et al., 2016; Yu et al., 2020). To date, there are no FDA-approved 
medications or conclusive evidence to support any pharmacological agent for the treatment of 
core social impairment in ASD (Barnard-Brak et al., 2016; McClellan et al., 2016; Sanchack & 
Thomas, 2016). Since the legalization of medical cannabis, certain patient populations have an 
additional option for treating ASD symptoms that are not managed with the available therapy and 
pharmacotherapy.  
Clinical question  
 The following clinical question guided this systematic literature review: In children (2 to 
21 years of age) with autism, does medical cannabis treatment improve ASD symptoms (core and 
noncore behaviors, comorbid conditions)? 
Clinical significance for advanced practice  
 There are few FDA-approved medications for noncore behaviors and no 
pharmacotherapy for core behaviors. To access medical cannabis in Minnesota, a provider 
(medical doctors [MD’s], Osteopaths (DO), Advanced Practice Registered Nurses [APRN’s]) 
certifies that the patient has a qualifying condition and follows up with the patient according to 
that state's regulations (Buppert & Klein, 2021). Qualifying conditions vary between the states, 
but as of 2021, fourteen states have included autism as a qualifying condition for medical 
cannabis use (MAMMA, n.d.). Patients rely on the expert knowledge of the provider to assist 
them in making informed decisions. The certifying provider must know the current state of 
evidence regarding cannabis treatment of ASD to properly advise the patient on their risk, 
benefits, and potential adverse side effects.  




Search strategies  
  The search for published literature was completed using the following databases: 
Academic Search Premier (ASP), CINAHL Plus with Full Text (CINAHL), ProQuest/Medline 
(PQ/ML), Nursing and Allied Health Database (NAHD), PubMed, Health Source: 
Nursing/Academic Edition (HS/NAE), Cochrane Central Register of Controlled Trials (CCRCT), 
and ClinicalTrials.gov (CT). These databases provide a diverse collection of articles from 
multiple disciplines (medical, nursing, psychology) and cover all medical topics (research, 
clinical practice, controlled trials, medical studies on human volunteers). Refer to Table 1 in the 
Appendix for a full description of subjects covered by each database. The literature search was 
completed on October 20, 2020 (ASP, CINAHL, PQ/ML, NAHD, PubMed, HS/NAE) and 
December 8, 2020 (ASP, CCRCT, CT). The literature published dates for all databases, except 
CT, were limited to the past 10 years. All dates were included for studies from CT.  All searches 
were limited to studies published in the English language. Other restrictions varied between the 
different databases. Refer to Table 1 in the Appendix for listing of complete restrictions.  
Study selection 
 Keywords used for searches in ASP, CINAHL, PQ/ML, NAHD, PubMed, HS/NAE, and 
CCRCT include medical cannabis, medical marijuana, cannabinoid, autism, ASD, autism 
spectrum disorder. Additional keywords used for ASP searches include ASD, autism spectrum 
disorder, children, adolescents, youth, child, teenager, and cannabidiol. Cannabidiol was an 
additional keyword used for searches in CCRCT. The keywords used for searches in CT include 
autism spectrum disorder, cannabinoid, and cannabidiol. The number of article ‘hits’ from the 
keywords noted above was recorded for each database. The author reviewed study bibliographies 
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for additional references that may have been missed from the database search. Refer to Table 2 in 
the Appendix for full details on keyword search combinations and article hits. 
Inclusion/exclusion criteria 
 Studies were included if they were written in English, published as full papers in peer-
reviewed journals within the past ten years (since 2010), and met the following criteria: (a) the 
population included individuals with a diagnosis of autism spectrum disorder, between the ages 
of 2 to 21 years, (b) the intervention involved cannabinoids, such as cannabidiol (CBD), delta-9-
tetrahydrocannabinol (THC), administered at any dose and any form, (c) studies with or without 
a comparison group (placebo or other forms of treatment), and (d) any outcome was considered, 
for the purposes of this review. No limits were placed on study designs (case report, case series, 
retrospective, observational longitudinal, randomized, or controlled clinical trials).  
 Title and abstract screening were conducted on searches with ten or fewer hits. After 
eliminating duplicate articles, twelve articles remained for full-text screening. Four articles met 
inclusion criteria after full-text review. The eight articles were excluded due to one or more of 
the following reasons: not specific to autism spectrum disorder, not specific to the target ages 
(two to 21), not specific to CBD or THC treatment, and not a quantitative research design. Refer 
to Table 3 in the Appendix for the specific inclusion and exclusion rationale used for each study. 
Literature review process 
 The four articles that met the inclusion criteria were reviewed by the author in full, data 
was abstracted, and findings analyzed. The following variables were abstracted: study purpose, 
population age and comorbidities, study design and level of evidence, assessment instruments, 
intervention, key findings, and practice implications. The level of evidence (LOE) was classified 
according to the hierarchy of evidence described by Melnyk and Fineout-Overholt (2015). The 
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four studies include one level V prospective cohort study without a control group, one level V 
retrospective cohort study without a control group, one level V prospective observational study 
without a control group, and one level VI case report. Refer to Table 4 in the Appendix for 
further detail on data abstraction of included articles. 
Methodological assessment 
Relevant studies may have been excluded due to one or more of the following factors: 
limiting title/abstract screening to searches with ten or fewer hits, excluding non-English studies, 
excluding other forms of cannabinoids (cannabinol, cannabigerol, cannabichromene, 
tetrahydrocannabivarin), and excluding the scientific name of cannabis (cannabis Sativa). The 
addition of a second reviewer for study selection, data abstraction, and assessment of the 
evidence level may decrease author bias and improve the validity and reliability of this 
systematic literature review.  
Literature Review 
Study characteristics 
 This literature review included three level V studies (prospective cohort study, 
retrospective cohort study, and prospective observational study) and one level VI case report. All 
four studies were published within the past two years. Sample sizes ranged from one (Barchel et 
al., 2019) to 188 (Bar-Lev Schleider et al., 2019). The age range of the participants was four to 
twenty-two years old. All studies assessed the effect of cannabinoids (cannabidiol and delta-9-
tetrahydrocannabinol) in treating one or more of the following: ASD core behaviors, ASD 
noncore behaviors, and comorbid conditions. The ASD core behavior, social communication, 
was assessed in three studies (Aran et al., 2019; Bar-Lev Schleider et al., 2019; Ponton et al., 
2020). Barchel et al. (2019) reported social communication deficits in their population but did 
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not measure the effects of cannabinoids on social communications. Noncore behaviors and 
comorbid conditions reviewed by one of the four studies include severe behaviors based on the 
Clinical Global Impression Scale score of 6 or 7 and anxiety (Aran et al., 2019); self-injury, rage 
attacks, hyperactivity, sleep problems, and anxiety (Barchel et al., 2019); restlessness, rage 
attacks, agitation, epilepsy, attention deficit hyperactivity disorder, Tourette syndrome, celiac 
disease, sleep problems, anxiety, and depression (Bar-Lev Schleider et al., 2019); and 
aggressiveness, irritability, concentration, epilepsy, anxiety, social anxiety, and sleep 
dysregulation (Ponton et al., 2020).  
 Cannabinoid treatment contained cannabidiol (CBD) and delta-9-tetrahydrocannabinol 
(THC) in a 20:1 ratio in all studies. Bar-Lev Schleider et al. (2019) also included treatment doses 
of 30% CBD and 1.5% THC, and 3% THC in some cases with severe aggression and violent 
behaviors. The daily dose given varied based on tolerability and body weight (Aran et al., 2019; 
Barchel et al., 2019; Bar-Lev Schleider et al., 2019; Ponton et al., 2020). Cannabinoid treatment 
was given as adjuvant therapy in three studies (Aran et al., 2019; Bar-Lev Schleider et al., 2019; 
Ponton et al., 2020). Barchel et al. (2019) did not indicate concomitant use of medications in 
their participants. All four studies did not include a control or comparison group (Aran et al., 
2019; Bar-Lev Schleider et al., 2019; Ponton et al., 2020). One study compared the improvement 
in cannabinoid treatment to published conventional treatments and found that cannabinoid 
treatment was not inferior to the conventional treatments (Barchel et al., 2019).  
 Symptom assessment tools varied between the studies under review, and some of the 
assessment tools are not validated. Bar-Lev Schleider et al. (2019) conducted a symptoms 
inventory and global assessment through structured questionnaires at intake and post-treatment 
(at one month and six months); symptom improvement was rated as "significant improvement”, 
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“moderate improvement”, or “cannabis did not help." Barchel et al. (2019) assessed the ASD 
comorbid symptom changes with phone questionnaires graded as “improvement”, “no change”, 
or “worsening” symptoms. Ponton et al. (2021) assessed noncore and comorbid condition 
changes with a visual analog scale (0 -10), Children’s Sleep Habits Questionnaire, and the Adult 
Autism Spectrum Quotient score for core symptoms. Aran et al. (2019) measured outcomes with 
the Caregiver Global Impression of Change scale, the Home Situations Questionnaire-Autism 
Spectrum Disorder, and the Autism Parenting Stress Index. Three studies reported adverse side 
effects (Aran et al. (2019; Barchel et al. (2019; Bar-Lev Schleider et al., 2019). Barchel et al. 
(2019) coded side effects according to the Medical Dictionary for Regulatory Activities. A 
modified Liverpool Adverse Events Profile was used by Aran et al. (2019) to assess side effects. 
Bar-Lev Schleider and colleagues (2019) inquired for side effects in their questionnaire. No side 
effects were reported by Pronto et al. (2020). 
Synthesis of research 
Core behaviors 
Social communication status improved with cannabis treatment, ranging from 30% (Bar-
Lev Schleider et al., 2019) to 47% improvement (Aran et al., 2019). Ponton et al. (2020) reported 
talkativeness improved by four points from a baseline of zero out of 10 scale. These findings 
suggest a benefit of cannabinoid treatment for social communication, a core behavior of ASD. A 
review by Karhson et al. (2016) emphasize that current evidence only supports the 
endocannabinoid signaling role in nonverbal motor-related aspects of social communications. 
However, they noted that the left hemisphere cortical regions have high concentrations of 
cannabinoid receptors and are associated with verbal language functions (Karhson et al., 2016), 
possibly explaining the improvement in communication noted in these studies. Other core 
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symptoms of ASD, such as restricted and repetitive patterns of behavior, interests, or activities, 
were not assessed in the studies reviewed. Bar-Lev Schleider et al. (2019) assessed tic disorder in 
their population and noted 80% of children reported improvement in symptoms. The ECS is 
involved in motor control (Zou & Kumar, 2018), but due to the lack of data among these studies, 
it is unclear if motor functions improve with cannabis without further study.  
Noncore behaviors 
 Three studies examined the effects of medical cannabis on specific noncore behaviors. 
Barchel et al. (2019) examined self-injury and rage attacks. Restlessness, rage attacks, and 
agitation were the most common behaviors noted by Bar-Lev Schleider et al. (2019). 
Aggressiveness and irritability were assessed by Ponto et al. (2020). Aran et al. (2019) did not 
report specific behaviors in their study population, yet behaviors were assessed with the Clinical 
Global Impression Scale; all participants had a score of six or seven indicating severe behaviors 
(Aran et al., 2019). All four studies observed improvement in noncore behaviors across studies. 
Barchel and colleagues (2019) described that of the children who reported self-injury and rage 
attacks (n = 34), 67.6% indicated ‘improvement’ in those behaviors. Bar-Lev Schleider et al. 
(2019) reported ‘improvement’ at six months in 89.8% of the children (n = 170) with 
restlessness, 89.0% of the children (n = 150) with rage attacks, and 83.8% of children (n = 148) 
with agitation. Ponto et al. (2019) indicated a decrease in aggressiveness (0/10) and decrease in 
irritability (2/10). In the study by Aran et al. (2019), behavior problems were described as ‘much 
improved’ or ‘very much improved’ in 61% of the children. The high percentage of children that 
reported improvement in noncore behaviors in all four studies suggests there are benefits of 
cannabinoid treatment. However, it is unknown if improvement in noncore behaviors is due to 
cannabinoid treatment or the result of improved comorbid conditions such as anxiety, ADHD, 
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and sleep dysregulation. These comorbid conditions can also have similar behaviors as 
presenting noncore ASD symptoms.  
Comorbid conditions 
Compared to the normal population, individuals with ASD have higher rates of 
concurrent medical conditions, including psychiatric conditions (Neumeyer et al., 2018; Rosen et 
al., 2018; Tye et al., 2019), epilepsy (Lukmanji et al., 2019; Thomas et al., 2016; Tye et al., 
2019), sleep disturbances (Neumeyer et al., 2018; Tye et al., 2019), gastrointestinal dysfunction 
(Neumeyer et al., 2018; Tye et al., 2019), and immune dysfunction (Tye et al., 2019).  The 
common comorbid conditions between the four studies include anxiety (Aran et al., 2019; 
Barchel et al., 2019; Bar-Lev Schleider et al., 2019; Ponto et al., 2020), epilepsy (Aran et al., 
2019; Bar-Lev Schleider et al., 2019; Ponto et al., 2020), sleep problems/dysregulation (Barchel 
et al., 2019; Bar-Lev Schleider et al., 2019; Ponto et al., 2020), and ADHD/ hyperactivity/ 
concentration (Barchel et al., 2019; Bar-Lev Schleider et al., 2019; Ponto et al., 2020).  
 Anxiety. Anxiety is the only comorbid condition addressed in all four studies with 
improvement in symptoms noted in each of them (Aran et al., 2019; Barchel et al., 2019; Bar-
Lev et al., 2019; Ponton et al., 2020). The improvement in anxiety symptoms ranged from 
23.5 % (Barchel et al., 2019) to 88.8% (Bar-Lev et al., 2019). Ponton et al. (2020) reported a 7-
point improvement in overall anxiety and social anxiety from a baseline of 10/10. The findings 
of these four studies suggest that cannabinoid treatment may decrease anxiety symptoms in 
children with ASD. These findings are consistent with evidence from both human and animal 
studies reporting CBD anxiolytic effects (Blessing et al., 2015; Crippa et al., 2011; Vanessa et al., 
2017). 
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 Epilepsy. Epilepsy was assessed in three studies based on medication use before and after 
initiation of cannabinoid treatment. Aran et al. (2019) reported that 33% of the children received 
less medication or lower doses after starting on cannabinoid treatment, 24% stopped taking 
medications, and 8% received more medications or higher doses but did not indicate if those 
medications were specific to epilepsy. Bar-Lev Schleider et al. (2019) reported antiepileptic use 
in 26.0% of their participants; follow up at six months found 13% of the participants had stopped 
taking antiepileptic medications. In the case study by Ponton et al. (2020), the patient trialed a 
decrease in their antiepileptic medication and was not successful; the medication was titrated 
back to its initial dose. The findings of the studies reviewed indicate relatively small benefits of 
combination cannabidiol and THC treatment for epilepsy, likely due to the lower dosing used in 
these studies. The literature supports high-dose CBD as effective treatment of intractable 
seizures, which has also been approved by the FDA (Devinsky et al., 2017, Devinsky et al., 
2018; FDA, 2018; Thiele et al., 2018).  
 Sleep problems/dysregulation. Sleep problems/dysregulation was assessed in three 
studies. Sleep improvement ranged from 58.6% (Bar-Lev et al, 2019) to 71.4% (Barchel et al., 
2019) after initiating cannabinoid therapy. Ponto et al. (2020) reported a 1-2 hour increase in the 
number of hours slept after starting cannabinoid treatment. These findings suggest improvement 
in sleep problems/dysregulation with cannabinoid therapy. Kesner and Lovinger (2020), Russo et 
al. (2007), and Shannon et al. (2019) examined the treatment of sleep disorders with CBD and 
THC combination therapy and also noted improved sleep.  
 ADHD/hyperactivity/concentration. ADHD/hyperactivity/concentration was measured in 
three studies that indicated improvement in concentration after starting cannabinoid treatment. 
Bar-lev Schleider et al. (2019) reported an increase in concentration from 0% to 14% of children; 
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2 points improvement in concentration was reported by Ponto et al. (2020), and 64.8% reported 
improvement in ADHD symptoms post starting treatment (Berchal et al., 2019). These findings 
suggest improvement of concentration in their study population. However, all three studies also 
report improved sleep problems/dysregulation, which can influence cognition, memory, 
performance deficits, and behavior problems (Medic et al., 2017).   
 Two studies reviewed changes in concomitant use of medications and cannabis. They 
reported 56% (Bar-Lev Schleider et al., 2019) to 82% (Aran et al., 2019) of children taking 
medications for behavioral problems before the study. Antipsychotics, mood stabilizers, 
hypnotics/sedatives, and SSRIs are among the most common among their participants. After 
cannabis treatment was initiated, 33% (Aran et al., 2019) to 34.3% (Bar-Lev Schleider et al., 
2019) of children received fewer medications or a lower dosage of the medication. The results of 
these studies indicate the positive effects of cannabinoid treatment on decreasing concomitant 
use of medications. 
Side effects 
 The most common side effects include sleep disturbance (Aran et al., 2019), somnolence 
and decreased appetite (Barchel et al., 2019), and restlessness (Bar-Lev Schleider et al., 2019). 
Ponto et al. (2020) did not report any side effects. One case of psychosis that requires 
antipsychotic treatment was reported by Aran et al. (2019). They indicated the psychosis was 
likely due to a cannabinoid combination with a high THC concentration (Aran et al., 2019). 
Adolescents have been reported to have an increased risk of adverse effects for psychosis 
(Ludman et al., 2015), especially in those with a history of schizophrenia or genetic 
predisposition for schizophrenia (Burnett, 2016). 
Quality indicators  
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 The effects of cannabis on ASD behavior symptoms are highly consistent between the 
studies reviewed. There was abundant literature on the effects of the ECS on human and rodent 
studies supporting evidence on potential effects caused by alterations in the ECS with exogenous 
cannabinoids. The conclusions made by the authors of these studies were supported by their data 
and other published works of literature. The studies in this review provide novel data and 
insights on the effects of cannabis use in ASD, a topic that lack human research, especially in the 
pediatric population.  
Gaps in the literature 
 Based on the findings from this review, evidence for cannabis treatment of core ASD 
symptoms is still lacking. Findings suggest that there may be some benefit to social 
communication and tic disorder, but the evidence is not conclusive on the effectiveness of 
cannabis for treating social communication or tic disorders. Further studies are needed to address 
core ASD symptoms specifically.  
 The dosing of cannabinoids varied between participants and between the studies, which 
does not provide sufficient data for analyzing dosing safety and efficacy. Most of the participants 
were using concomitant medications, which leads to the question of whether the participants' 
side effects were related to the cannabis or perhaps drug-drug interaction.    
Discussion 
 The existing literature on ASD treatment with cannabis is limited. Despite the beneficial 
findings reported in the studies in this review, all were considered low levels of evidence (V-VI) 
(Melnyk & Fineout-Overholt, 2015). The literature lacks substantial evidence to support 
cannabinoid treatment of ASD core and noncore behaviors and comorbid conditions in children. 
The studies in this literature review were observational, with small sample sizes making it is 
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difficult to generalize the results; despite the absence of strong evidence supporting the use of 
cannabis for treating ASD symptoms. These studies provide insight into the therapeutic effect of 
cannabis in treating several ASD symptoms, which is also supported by preclinical findings and 
understanding of the ECS. The preclinical data along with key studies in this literature review 
warrant further research with large, randomized controlled trials.   
Implications for future research 
 The findings of this literature review indicate beneficial effects of cannabis in treating 
ASD symptoms and some comorbid conditions in children, but they do not provide strong 
evidence due to the low-level study designs of research contained in this review. The finding 
provides strong support for further random controlled trials to determine safety and efficacy in 
cannabis use in treating ASD symptoms and comorbid conditions in children, as well as 
longitudinal studies on the long-term effects of cannabis on the developing brain. 
Clinical practice recommendations 
 The literature is sparse and does not recommend cannabis as an evidenced-based 
treatment for ASD symptoms and comorbid conditions. However, the potential benefits 
identified in these studies strongly support further research and consideration of medical 
cannabis as an adjunct treatment after careful review of risks, benefits, and considerations for 
accessibility. Key considerations for accessibility include legal status of medical cannabis in the 
state in which the patient and provider reside, the feasibility of medical cannabis use due to cost 
and the patient’s ability to access a dispensary. Furthermore, providers should use validated tools 
for symptom assessment in order to obtain reliable data on efficacy of this intervention. Patient’s 
new to medical cannabis should start with low THC products due to the risk of adverse effects 
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with high THC products (psychosis, hyperemesis) and be titrated carefully based on symptom 
profile and side effects. 
Recommendations for research 
 Research designs such as large double-blinded research control trials are needed to assess 
the safety and efficacy of cannabinoid treatment of ASD symptoms in children. Additional 
research is needed to assess the efficacy and safety of different cannabinoid strains, 
concentrations, dosing, titration recommendations, and route in children. Further research is 
needed to determine ASD symptoms assessment tools for assessing the effects of medical 
cannabis treatment in children. Symptom assessment tools should be objective, standardized, and 
validated to provide reliable and valid data. Research concerning the drug-drug interactions of 
cannabinoids is essential as ASD treatment is often accompanied by pharmacotherapy of 
comorbid conditions. Longitudinal studies are needed to study the effects of cannabis use on the 
developing brain. 
Recommendations for policy changes 
 At the federal level, marijuana/cannabis remains classified as a Schedule I substance 
under the Controlled Substances Act. “Schedule I substances are considered to have a high 
potential for dependency and no accepted medical use, making the distribution of marijuana a 
federal offense” (National Conference of State Legislatures, 2021). As a result of this 
classification, health insurances do not provide any coverage or copay for medical cannabis and 
the burden of cost falls entirely on the patient alone. The high cost of medical cannabis limits its 
accessibility to only patients with the ability to pay out of pocket. 
 The state medical cannabis laws only permit possession and use of cannabis within the 
state where the patient received the certification(Walters, 2021). This can be interpreted to mean 
                       
 
20 
that crossing state lines with medical cannabis is illegal as federal laws supersede state laws 
(Walters, 2021). Patients will have to use alternative treatments when traveling, which is 
disruptive to their disease management with medical cannabis. The conflicting state and federal 
policies on medical cannabis make navigating care difficult for patients and providers. 
Conclusion 
 With the legalization of cannabis for medicinal use, providers will likely encounter 
patients seeking this treatment option. The few studies that exist report benefits in ASD 
symptoms and comorbid conditions, with the most common side effects being somnolence and 
the potential for psychosis with higher THC concentration. There are studies that report potential 
harm on the developing brain with cannabis use (Battistella et al., 2014; Lubman et al., 2015). 
RCT studies are needed to assess the safety of cannabis in the pediatric population, as children as 
young as two years old can qualify for medical cannabis use in some states. There is not enough 
evidence to support the use of cannabis as a primary or alternative treatment for ASD symptoms 
in children, yet findings suggest potential benefits for cannabis use as an adjunct therapy in 
children. The consideration for using cannabis as an adjunct therapy should occur after careful 
review of the benefits and barriers of the therapeutic use of cannabis with parent(s) and the child. 
The analysis of this literature review and related recommendations are consistent with two other 
reviews on the current state of evidence of cannabis use in ASD (Agarwal et al., 2019; Poleg et 
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children with ASD. 



















































-CBD and THC 
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treatment (p = 
0.232)   
-Overall: 
Improvement: 



























12) and decreased 




Saban, N., Meiri, 
G., & Novack, V. 


















and to describe its 
safety and efficacy. 

































-CBD and THC 
at a 20:1 ratio 
-30% CBD & 
1.5% THC 
-additional 3% 




-After 6 months 
155 patients 
remain in active 
treatment, of those 












8 (8.6%) having 




inventory (3 most 
common): 












the child global 
assessment. 
 





Cannabis is well 
tolerated; less than 
15% stopped 
treatment at 6 
months. 

























prior to treatment 




(8.8%) reported no 
change, 1 (1.2%) 
reported symptom 
disappeared. 
-Rage attacks: 150 
patients (79.8%) 
reported symptom 
prior to treatment 
and after 6 months 
65 (89%) reported 
improvement, 7 
(9.5%) reported no 






symptoms prior to 
treatment and after 













and hypnotics and 
sedatives.  
 
Most common side 
effect was 
restlessness. 






































Quality of life:  
-31.3% reported 
good quality of 
life prior to 
treatment and 
66.8% after 6 
months (p<0.001) 
-42% of parents 
reported positive 
mood prior to 
treatment and 
63.5% after 6 
months (p<0.001) 
-26.4% reported 
no difficulty in 
ability to dress and 
shower 
independently 
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prior to treatment 
and 42.9% after 6 
months (p<0.001) 
-3.3% reported 










Medication use:  
-Of the 93 patients 
that responded at 6 
months, 67 
reported chronic 
medication use; 6 
patients reported 






remain the same 
and 23 patients 
(34.3%) reported a 
decrease, mainly 
of the following: 
antipsychotics, 
antiepileptics, 
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antidepressants 




-At 6 months 23 
patients (25.2%) 
reported at least 
one side effect; the 
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therapy: a case 





This case report 
describes the 
clinical 






social deficits who 
benefited clinically 
with low doses of 
Cannabidiol-based 
extract (CBE). 
N = 1 










severity on a 
visual analog 



















and THC in 20:1 
ratio 
 
VAS (0 = least 
























as well as anxiety, 
sleep disturbance, 
and weight.  
 
 





























VAS (0 = quiet, 10 
= very talkative) 
-Talkativeness in 
social situation: 
initial (0/10), 9 
months improved 
by 4 points 
 
VAS (0 = 
unfocused, 10 = 
very focused) 
-Concentration: 
initial (4/10), at 9 
months improved 
by 2 points 
 
CSHQ: initial (5 to 
6 hours of sleep), 
at 9 months (7 
hours of sleep) 
Adult (AQ) was a 
normal score of 10 
 
 
